




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C07C 229/42, A61K 32/195</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/11605</b> <b>(43) International Publication Date:</b> 11 March 1999 (11.03.99)
<b>(21) International Application Number:</b> PCT/EP98/05414 <b>(22) International Filing Date:</b> 26 August 1998 (26.08.98) <b>(30) Priority Data:</b> 60/069,837           28 August 1997 (28.08.97)      US 60/057,803           28 August 1997 (28.08.97)      US <b>(71) Applicant (for all designated States except AT):</b> NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). <b>(72) Inventors:</b> NOVARTIS-ERFINDUNGEN VERWALTUNGS-GESELLSCHAFT MBH; Brunner Strasse 59, A-1235 Vienna (AT). FUJIMOTO, Roger, Aki; 21 Molly Stark Drive, Morristown, NJ 07960 (US). MCQUIRE, Leslie, Wighton; 17 Crown Drive, Warren, NJ 07059 (US). MUGRAGE, Benjamin, Biro; 10 Courter Street, Basking Ridge, NJ 07920 (US). VAN DUZER, John, Henry; 304 County Road 579, Asbury, NJ 08802 (US). XU, Daqiang; 12 Kathryn Drive, Whippany, NJ 07981 (US). <b>(74) Agent:</b> BECKER, Konrad; Novartis AG, Patent- und Markenabteilung, Lichtstrasse 35, CH-4002 Basel (CH).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND DERIVATIVES		
<div style="text-align: center;">  <p>(I)</p> </div>		
<b>(57) Abstract</b> <p>Disclosed are the compounds of formula (I), wherein R is methyl or ethyl; R<sub>1</sub> is chloro or fluoro; R<sub>2</sub> is hydrogen or fluoro; R<sub>3</sub> is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy; R<sub>4</sub> is hydrogen or fluoro; and R<sub>5</sub> is chloro, fluoro, trifluoromethyl or methyl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof; as selective COX-2 cyclooxygenase inhibitors.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND DERIVATIVES

The invention relates to 5-alkyl-2-arylaminophenylacetic acids and derivatives thereof as defined herein which are particularly potent and selective cyclooxygenase-2 (COX-2) inhibitors, methods for preparation thereof, pharmaceutical compositions comprising said compounds, methods of selectively inhibiting COX-2 activity and of treating conditions in mammals which are responsive to COX-2 inhibition using said compounds or pharmaceutical compositions comprising said compounds of the invention.


Various substituted 2-arylaminophenylacetic acids and derivatives thereof have been disclosed e.g. in J. Med. Chem. 33, 2358 (1990), U.S. patents 3,558,690, 3,652,762, 4,173,577 and 4,548,952, DE 3445011, and in PCT applications WO 97/09977 and WO 96/00716 as non-steroidal antiinflammatory agents and cyclooxygenase inhibitors. As to 5-alkyl-2-arylaminophenylacetic acids, the only example known to be described in the literature is 5-methyl-2-(2,6-dimethylanilino)-phenylacetic acid and its sodium salt (U.S. patent 3,558,690) for which no biological data has been reported.

Non-steroidal antiinflammatory agents block prostaglandin synthesis by inhibition of the enzyme cyclooxygenase. Cyclooxygenase is now known to comprise a constitutive isoform (cyclooxygenase-1, COX-1) and an inducible isoform (cyclooxygenase-2, COX-2). COX-1 appears responsible for protective beneficial features of prostaglandins, e.g. for the gastrointestinal tract, kidney, etc., while the inducible isoform COX-2 appears responsible for pathological conditions associated with prostaglandins, such as inflammatory conditions. A limitation to the use of classical nonsteroidal antiinflammatory drugs (NSAIDs including diclofenac sodium which is the sodium salt of 2,6-dichloroanilinophenylacetic acid) is gastrointestinal toxicity now attributed to the inhibition of the COX-1 isoform of cyclooxygenase. Selective inhibition of inducible COX-2 in vivo has been reported to be antiinflammatory and non-ulcerogenic (Proc. Natl. Acad. Sci. (USA) 1994; 91:3228-3232).

The present invention provides novel 5-alkyl substituted 2-arylaminophenylacetic acids and derivatives which surprisingly inhibit COX-2 without significantly inhibiting COX-1. The invention thus provides novel nonsteroidal antiinflammatory agents which are surprisingly free

of undesirable side effects usually associated with the classical nonsteroidal antiinflammatory agents, such as gastrointestinal and renal side effects.

The invention relates to compounds of formula I



wherein R is methyl or ethyl;

R<sub>1</sub> is chloro or fluoro;

R<sub>2</sub> is hydrogen or fluoro;

R<sub>3</sub> is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy;

R<sub>4</sub> is hydrogen or fluoro; and

R<sub>5</sub> is chloro, fluoro, trifluoromethyl or methyl;

pharmaceutically acceptable salts thereof; and

pharmaceutically acceptable prodrug esters thereof.

A particular embodiment of the invention relates to the compounds of formula I wherein R is methyl or ethyl; R<sub>1</sub> is chloro or fluoro; R<sub>2</sub> is hydrogen; R<sub>3</sub> is hydrogen, fluoro, chloro, methyl or hydroxy; R<sub>4</sub> is hydrogen; and R<sub>5</sub> is chloro, fluoro or methyl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof.

A preferred embodiment relates to the compounds of formula I wherein R is methyl or ethyl; R<sub>1</sub> is fluoro; R<sub>2</sub> is hydrogen; R<sub>3</sub> is hydrogen, fluoro or hydroxy; R<sub>4</sub> is hydrogen; and R<sub>5</sub> is chloro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.

Another preferred embodiment of the invention relates to compounds of formula I wherein R is ethyl or methyl; R<sub>1</sub> is fluoro; R<sub>2</sub> is hydrogen or fluoro; R<sub>3</sub> is hydrogen, fluoro, ethoxy or hydroxy; R<sub>4</sub> is hydrogen or fluoro; and R<sub>5</sub> is chloro, fluoro or methyl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.

Further preferred are said compounds wherein R is methyl or ethyl; R<sub>1</sub> is fluoro; R<sub>2</sub>-R<sub>4</sub> are hydrogen or fluoro; and R<sub>5</sub> is chloro or fluoro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.

A further embodiment of the invention relates to the compounds of formula I wherein R is methyl or ethyl; R<sub>1</sub> is fluoro; R<sub>2</sub> is fluoro; R<sub>3</sub> is hydrogen, ethoxy or hydroxy; R<sub>4</sub> is fluoro; and R<sub>5</sub> is fluoro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.

Another preferred embodiment of the invention relates to the compounds of formula I wherein R is methyl; R<sub>1</sub> is fluoro; R<sub>2</sub> is hydrogen; R<sub>3</sub> is hydrogen or fluoro; R<sub>4</sub> is hydrogen; and R<sub>5</sub> is chloro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.

Particular embodiments of the invention relate to compounds of formula I

(a) wherein R is methyl; R<sub>1</sub> is fluoro; R<sub>2</sub> is hydrogen; R<sub>3</sub> is hydrogen; R<sub>4</sub> is hydrogen; and R<sub>5</sub> is chloro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof;


(b) wherein R is methyl; R<sub>1</sub> is fluoro; R<sub>2</sub> is hydrogen; R<sub>3</sub> is fluoro; R<sub>4</sub> is hydrogen; and R<sub>5</sub> is chloro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof;

(c) wherein R is ethyl; R<sub>1</sub> is fluoro; R<sub>2</sub> is fluoro; R<sub>3</sub> is hydrogen; R<sub>4</sub> is fluoro; and R<sub>5</sub> is fluoro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof; and

(d) wherein R is ethyl; R<sub>1</sub> is chloro; R<sub>2</sub> is hydrogen; R<sub>3</sub> is chloro; R<sub>4</sub> is hydrogen; and R<sub>5</sub> is methyl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.

The general definitions used herein have the following meaning within the scope of the present invention.

Pharmaceutically acceptable prodrug esters are ester derivatives which are convertible by solvolysis or under physiological conditions to the free carboxylic acids of formula 1. Such esters are e.g. lower alkyl esters (such as the methyl or ethyl ester), carboxy-lower alkyl esters such as the carboxymethyl ester, nitrooxy-lower alkyl esters (such as the 4-nitrooxybutyl ester), and the like. Preferred are the compounds of formula 1a



wherein R and R<sub>1</sub>-R<sub>5</sub> have meaning as defined hereinabove for compounds of formula 1; and pharmaceutically acceptable salts thereof.

Pharmaceutically acceptable salts represent metal salts, such as alkaline metal salts, e.g. sodium, potassium, magnesium or calcium salts, as well as ammonium salts, which are formed e.g. with ammonia and mono- or di-alkylamines, such as diethylammonium salts, and with amino acids such as arginine and histidine salts.

A lower alkyl group contains up to 7 carbon atoms, preferably 1 to 4 carbon atoms and represents for example methyl, ethyl, propyl or butyl, and may be straight chain or branched.

The compounds of the present invention are particularly useful or may be metabolically converted to compounds which are particularly useful as COX-2 selective cyclooxygenase inhibitors. They are thus particularly useful for the treatment of cyclooxygenase dependent

disorders in mammals, including inflammation, pyresis, pain, osteoarthritis, rheumatoid arthritis, migraine headache, neurodegenerative diseases (such as multiple sclerosis), Alzheimer's disease, osteoporosis, asthma, lupus and psoriasis.

The compounds of the present invention are further useful for the treatment of neoplasia particularly neoplasia that produce prostaglandins or express cyclooxygenase, including both benign and cancerous tumors, growths and polyps. Compounds of the present invention may be employed for the treatment of any neoplasia as for example recited in International Patent Application Publication No. WO 98/16227, published 23 April 1998, in particular epithelium cell-derived neoplasia. Compounds of the present invention are in particular useful for the treatment of liver, bladder, pancreas, ovarian, prostate, cervical, lung and breast cancer and, especially gastrointestinal cancer, for example cancer of the colon, and skin cancer, for example squamous cell or basal cell cancers and melanoma.

The term "treatment" as used herein is to be understood as including both therapeutic and prophylactic modes of therapy, e.g. in relation to the treatment of neoplasia, therapy to prevent the onset of clinically or preclinically evident neoplasia, or for the prevention of initiation of malignant cells or to arrest or reverse the progression of premalignant to malignant cells, as well as the prevention or inhibition of neoplasia growth or metastasis. In this context, the present invention is, in particular, to be understood as embracing the use of compounds of the present invention to inhibit or prevent development of skin cancer, e.g. squamous or basal cell carcinoma consequential to UV light exposure, e.g. resultant from chronic exposure to the sun.

The compounds of the invention have activity in the above indications while substantially avoiding undesirable gastrointestinal ulceration associated with conventional cyclooxygenase inhibitors.

The compounds of the invention are also UV absorbers and are useful for blocking or absorbing UV radiation; for instance, for the treatment and prevention of sunburn, e.g. in suntan products

The compounds of the invention may also be used in ocular applications which include the treatment of ocular disorders, in particular of ocular inflammatory disorders, of ocular pain

including pain associated with ocular surgery such as PRK or cataract surgery, of ocular allergy, of photophobia of various etiology, of elevated intraocular pressure (in glaucoma) by inhibiting the production of trabecular meshwork inducible glucocorticoid response (TIGR) protein, and of dry eye disease.

The above-cited properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g. rats, mice, dogs, monkeys and isolated cells or enzyme preparations thereof. Said compounds can be applied in vitro in the form of solutions, e.g. aqueous solutions, and in vivo advantageously orally, topically or parenterally, e.g. intravenously. The dosage in vitro may range from about  $10^{-5}$  to  $10^{-9}$  molar concentrations. The dosage in vivo may range, depending on the route of administration, between about 1 and 100 mg/kg.

Cyclooxygenase inhibition is determined in vitro using cellular assays for inhibition of both cyclooxygenase-1 and cyclooxygenase-2.

The cellular assays for testing cyclooxygenase inhibitors are based on the fact that the cyclooxygenase enzyme (prostaglandin H synthase) catalyzes the rate limiting step in prostaglandin synthesis from arachidonic acid. Two enzymes mediate the reaction: COX-1 is a constitutive form of the enzyme whereas COX-2 is induced in response to various growth factors and cytokines. Cell lines have been established which express one form of the enzyme: a human skin fibroblast line which can be induced with IL-1 to synthesize COX-2, and the kidney epithelial cell line 293 which has been stably transfected to constitutively express COX-1. Both isoforms metabolize arachidonic into the stable metabolite prostaglandin  $E_2$ . Arachidonic acid can be added exogenously to increase output to easily measurable levels. The levels of prostaglandin  $E_2$  in the extracellular medium are assayed by radioimmunoassay as a measure of enzyme activity. The relative activities of each isoform are compared to assess compound selectivity.

In vitro cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibition is determined in the cell-based assays in order to assess the in vitro activity and selectivity for COX-2 inhibition, using a prostaglandin  $E_2$  radioimmunoassay. The cells utilized are primary human fibroblasts induced with interleukin-1 to produce COX-2, and the human kidney epithelial cell line 293 stably transfected to produce COX-1 constitutively. Cells are plated out into well plates in which the assay is performed. Fibroblasts are stimulated to synthesize COX-2 by treatment



overnight with IL-1; the 293 cells require no induction. Both cell lines are pre-treated with compound dilutions for 15 minutes at 37°C, then 40  $\mu$ M arachidonic acid is added as exogenous substrate for the production of PGE<sub>2</sub>, which is measured in supernatant by radioimmunoassay. For IC<sub>50</sub> determinations, compounds are tested at 5 concentrations in quadruplicate (highest concentration 30  $\mu$ M); the mean inhibition of PGE<sub>2</sub> (compared to cells not treated with compound) for each concentration is calculated, a plot made of mean % inhibition vs. log compound concentration for all experiments, and the overall IC<sub>50</sub> value calculated using a 4-parameter logistic fit.

Typically IC<sub>50</sub> values for compounds of formula I in the COX-2 inhibition assay are as low as about 0.005  $\mu$ M whereas IC<sub>50</sub> values in the COX-1 inhibition assay are greater than 30  $\mu$ M.

Illustrative of the invention, the compounds of examples 6, 9 and 18 have an IC<sub>50</sub> of about 0.13, 0.25, 0.007  $\mu$ M, respectively, for COX-2 inhibition with no significant COX-1 inhibition at 30  $\mu$ M.

The inhibition of prostaglandin-E<sub>2</sub> production produced by COX-2 can be determined in vivo in the lipopolysaccharide (LPS)-challenged subcutaneous air pouch model in the rat (see "Advances in Inflammation Research", Raven Press, 1986 and J. Med. Chem. 39, 1846 (1996)).

Female Lewis rats are anesthetized and then dorsal air pouches are prepared by subcutaneous injection of 10 ml of air through a sterile 0.45 micron syringe-adapted filter. Twenty-four hours after preparation, the air pouches are injected with LPS (8  $\mu$ g/pouch) suspended in sterile phosphate buffered saline. Compounds for evaluation are suspended in fortified cornstarch and administered by gavage one hour prior to LPS challenge. The pouch contents are harvested three hours after LPS challenge and PGE<sub>2</sub> levels present in the pouch fluids are measured by enzyme immunoassay. ED<sub>50</sub> values for inhibition of PGE<sub>2</sub> formation are calculated by least squares linear regression. Illustrative of the invention the compounds of examples 6, 9, 18 and 24 have an ED<sub>50</sub> in the range of about 0.2 mg/kg p.o. to about 0.6 mg/kg p.o..

The in vivo inhibition of thromboxane B<sub>2</sub> (TXB<sub>2</sub>) produced by COX-1 can be measured ex vivo in the serum of rats after oral administration of compound:

Briefly, rats are fasted overnight, administered compound in fortified cornstarch vehicle by gavage, and sacrificed by carbon dioxide inhalation 30 minutes to eight hours later. Blood is collected by cardiac puncture into tubes without anti-coagulant, allowed to clot and serum is separated by centrifugation. Serum is stored frozen for later analysis of thromboxane B<sub>2</sub> by radioimmunoassay. Each experiment contains the following groups (5-6 rats per group): vehicle control and test compounds, either at different doses or different time points.

Thromboxane B<sub>2</sub> data is expressed as a percentage of the levels measured in the vehicle control group. Illustrative of the invention the compounds 1(d), 1(g), 3(a), and 6(a) cause less than a 50% inhibition of serum thromboxane B<sub>2</sub> production at an oral dose which is 50-150 times the ED<sub>50</sub> value for in vivo COX-2 inhibition.

Antiinflammatory activity is determined using the carrageenan induced rat paw edema assay.

Sprague Dawley rats (200-225g) are fasted overnight, then orally dosed with the compound suspended in a fortified cornstarch solution. After one hour, a 0.1 ml volume of 1% carrageenan in saline is injected into the subplantar region of the left hind paw which causes an inflammatory response. At 3 hours post carrageenan, the rats are euthanatized and both hind paws are cut off at the paw hair line and weighed on an electronic balance. The amount of edema in the inflamed paw is determined by subtracting the weight of the non-inflamed paw (right) from the weight of the inflamed paw (left). The percent inhibition by the compound is determined for each animal as the percent paw weight gained as compared to the control average. ED<sub>30</sub> values are determined for each dose-response using the curve fitting formula,

$$100 / 1 + (\text{Drug Concentration} / \text{ED}_{50})^{\text{slope}}$$

Mean ED<sub>30</sub> values are calculated as the average of ED<sub>30</sub> values determined from independent dose response assays.

The gastric tolerability assay is used to assess gross ulceration in the rat, measured four hours after oral administration of the test compound. The test is carried out as follows:

Rats are fasted overnight, administered compound in fortified cornstarch vehicle by gavage, and sacrificed by carbon dioxide inhalation four hours later. The stomachs are removed and gross gastric lesions counted and measured to give the total lesion length per rat. Each

experiment contains the following groups (5-6 rats per group): vehicle control, test compounds, and diclofenac as a reference compound.

Data are calculated as the mean number of ulcers in a group, the mean length of ulcers (mm) in the group and as the ulcer index (UI).

$UI = \text{mean length of ulcers in a group} \times \text{ulcer incidence}$

where ulcer incidence is the fraction of animals in the group with lesions (100% incidence is 1). Illustrative of the invention, the compounds of examples 6, 9, 18 and 24 are essentially free of any gastric ulcerogenic effect at 100 mg/kg p.o.

Intestinal tolerability can be determined by measuring the effect on intestinal permeability. Lack of increase in permeability is indicative of intestinal tolerability.

The method used is a modification of a procedure by Davies, et al. Pharm. Res. 1994; 11:1652-1656 and is based on the fact that excretion of orally administered  $^{51}\text{Cr-EDTA}$ , a marker of small intestinal permeability, is increased by NSAIDs. Groups of rats ( $\geq 12/\text{group}$ ) and administered a single, oral dose of test compound or vehicle by gastric intubation.

Immediately following compound dose, each rat is administered  $^{51}\text{Cr-EDTA}$  (5  $\mu\text{Ci}/\text{rat}$ ) by gastric intubation. The rats are placed in individual metabolic cages and given food and water *ad libitum*. Urine is collected over a 24 hour period. Twenty-four hours after administration of  $^{51}\text{Cr-EDTA}$  the rats are sacrificed. To quantify compound effect on intestinal permeability, the excreted  $^{51}\text{Cr-EDTA}$  measured in the urine of compound treated rats is compared to the excreted  $^{51}\text{Cr-EDTA}$  measured in the urine of vehicle treated rats. Relative permeability is determined by calculating the activity present in each urine sample as a percent of the administered dose after correcting for background radiation.

Illustrative of the invention, the compounds of examples 6, 9, 18 and 24 demonstrate no effect or only a minimal effect on intestinal permeability at a dose of 30 mg/kg p.o.

The analgesic activity of the compounds of the invention is determined using the well-known Randall-Selitto assay.

The Randall-Selitto paw pressure assay measures antinociception (analgesic activity) in inflamed tissue by comparing the pressure threshold in the inflamed paw of the rat after oral administration of test drug with that in the inflamed paw of rats administered corn starch vehicle orally.

Groups of 10 male Wistar rats weighing 40-50 gms are fasted overnight prior to testing. Hyperalgesia is induced by the injection of 0.1 ml of a 20% suspension of Brewer's yeast with a 26 gauge needle into the subplantar region of the right hindpaw. The left paw is not injected and is used as the control paw for determination of hyperalgesia. Vehicle (Fortified corn starch suspension 3%) at 10ml/kg, reference compound (diclofenac is run in every experiment at the same dose as test compounds) and test compounds at different doses suspended in vehicle at 10ml/kg are administered orally 2 hours after the yeast injection. The threshold for paw withdrawal is quantified with a Basile Analgesy-meter 1 hour after oral administration of test compounds. The nociceptive threshold is defined as the force in grams at which the rat withdraws its foot or vocalizes. Either vocalization or foot withdrawal is recorded as a response.


The data are analyzed by comparing the mean pain threshold of the corn starch vehicle-treated group for the inflamed and non-inflamed paws to that of individual drug-treated rats. Individual rats in the drug-treated groups and positive control (diclofenac) group are called reactors if the individual pain threshold in each paw exceeds the control group mean threshold by two standard deviations of that mean. The mean pain thresholds of the inflamed paw in the control group are compared to the individual pain thresholds of the inflamed paw in the test drug group. The non-inflamed control mean pressure threshold is compared to the non-inflamed individual pressure thresholds in the test groups. Results are expressed as number of reactors in each test group ( $n = 10$ ) for inflamed and non-inflamed paws. Percentages are calculated by dividing number of reactors by total number of rats used for a compound.

Illustrative of the invention the compounds of examples 6, 9, 18 and 24 all increase the pain threshold in the inflamed paw at 10 mg/kg administered orally. These compounds selectively elevate the pain threshold in the inflamed paw with no threshold elevation in the non-inflamed paw indicating a peripheral mechanism.


The antiarthritic effect of the compounds of the invention can be determined in the well-known chronic adjuvant arthritis test in the rat. Ophthalmic effects may be demonstrated using methods well known in the art.

The compounds of formula I can be prepared e.g.

(a) by coupling a compound of formula II or IIa




(II)



(IIa)



wherein R has meaning as defined above;  $R_a$  is lower alkyl, preferably isopropyl; and  $R_6$  and  $R_7$  represent lower alkyl; or  $R_6$  and  $R_7$  together with the nitrogen atom represent piperidino, pyrrolidino or morpholino;

with a compound of formula III




(III)

wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and  $R_5$  have meaning as defined above in the presence of copper and cuprous iodide to obtain a compound of formula IV or IVa




and hydrolyzing the resulting compound of formula IV or IVa to a compound of formula I; or

(b) for compounds in which R represents ethyl, by condensing a compound of formula V




wherein R<sub>1</sub>-R<sub>7</sub> have meaning as defined herein, with a reactive functional derivative of acetic acid, such as acetyl chloride, in a Friedel-Crafts acylation to reaction to obtain a compound of the formula VI



wherein  $R_1$ - $R_7$  have meaning as defined herein which is in turn hydrogenolyzed and then hydrolyzed to obtain a compound of formula I wherein R represents ethyl; or

(c) by hydrolyzing a lactam of formula VII



wherein R and  $R_1$ - $R_5$  have meaning as defined herein, with a strong base; and

in the above processes, if desired, temporarily protecting any interfering reactive groups and then isolating the resulting compound of the invention; and, if desired, converting any resulting compound into another compound of the invention; and/or if desired converting a free carboxylic acid of the invention into a pharmaceutically acceptable ester derivative thereof; and/or if desired, converting a resulting free acid into a salt or a resulting salt into the free acid or into another salt.

In starting compounds and intermediates, which are converted to the compounds of the invention in a manner described herein, functional groups present such as amino, hydroxy and carboxyl groups, are optionally protected by conventional protecting groups that are common in preparative organic chemistry. Protected hydroxy, amino and carboxyl groups are those that can be converted under mild conditions into free amino, hydroxy and carboxyl groups without other undesirable side reactions taking place. For example, hydroxy protecting groups are preferably benzyl or substituted benzyl groups.

The preparation of compounds of formula IV according to process (a) is carried out under conditions of a modified Ullmann condensation for the preparation of diarylamines, e.g. in the presence of copper powder and copper (I) iodide and potassium carbonate, in an inert high boiling solvent such as nitrobenzene, toluene, xylene or N-methylpyrrolidone, at elevated temperature, e.g. in the range of 100°-200°C, preferably at reflux temperature, according to general methodology described by F. Nohara, Chem. Abstr. 94, 15402x (1951) and Moser et al., J. Med. Chem. 33, 2358 (1990).

Intermediates of Formula IV wherein R<sub>1</sub> or R<sub>5</sub> is methyl or ethyl can be prepared from intermediates of formula IV, wherein R<sub>1</sub> or R<sub>5</sub> is bromo by reaction with tetramethyltin or tetraethyltin under conditions of a Heck reaction, that is in the presence of a palladium salt (such as Pd(OAc)<sub>2</sub> or PdCl<sub>2</sub>), a triarylphosphine (such as tri (o-tolyl)phosphine) and a base (such as triethylamine, sodium acetate) in a polar solvent such as dimethylformamide.

Hydrolysis of the resulting ortho-anilinophenylacetamides of formula IV is carried out in aqueous alkali hydroxide, e.g. in 6N NaOH in the presence of an alcohol (e.g. ethanol, propanol, butanol) at elevated temperature, such as reflux temperature of the reaction mixture.

The hydrolysis of esters of formula IVa is carried out according to methods known in the art, e.g. under basic conditions as described above for the compounds of formula IV or alternatively under acidic conditions, e.g. using methanesulfonic acid.

The starting materials of formula II or IIa are generally known or can be prepared using methodology known in the art, e.g. as described by F. Nohara in Japanese patent application No. 78/96,434 (1978).



For example, 5-methyl or 5-ethylanthranilic acid is converted to the ortho-diazonium derivatives followed by treatment with an alkali metal iodide in acid (e.g. sulfonic acid) to obtain 5-alkyl-2-iodobenzoic acid. Reduction to the corresponding benzyl alcohol (e.g. with diborane), conversion of the alcohol first to the bromide and then to the nitrile, hydrolysis of the nitrile to the acetic acid and conversion to the N,N dialkylamide according to methodology known in the art yields a starting material of formula II.

Alternatively, the starting materials of formula II wherein R is ethyl can be prepared by Friedel-Crafts acetylation of oxindole with e.g. acetyl chloride in the presence of aluminum chloride, reduction of the resulting ketone by e.g. catalytic hydrogenolysis, followed by hydrolytic cleavage of the resulting 5-ethyloxindole to 5-ethyl-2-aminophenylacetic acid. Diazotization in the presence of e.g. potassium iodide yields 5-ethyl-2-iodo-phenylacetic acid which is converted to an amide of formula II. Esters of formula IIa are prepared from the corresponding acids according to esterification methods known in the art.


The anilines of formula III are either known in the art or are prepared according to methods well-known in the art or as illustrated herein.

The preparation of 5-ethyl substituted compounds according to process (b) is carried out under conditions of Friedel-Crafts acylation e.g. in the presence of aluminum chloride in an inert solvent such as 1,2-dichloroethane, followed by hydrogenolysis, e.g. using palladium on charcoal catalyst, preferably in acetic acid as solvent, at room temperature and about 3 atmospheres pressure.


The starting materials of formula V are prepared generally as described under process (a) but starting with an amide of formula II in which R represents hydrogen, e.g. as described in J. Med. Chem. 33, 2358 (1990).

The preparation of the compounds of the invention according to process (c) can be carried out under conditions known in the art for the hydrolytic cleavage of lactams, preferably with a strong aqueous base, such as aqueous sodium hydroxide, optionally in the presence of an organic water miscible solvent such as methanol at elevated temperature in the range of about 50° to 100°C, as generally described in U.S. patent 3,558,690.

The oxindole starting materials are prepared by N-acylation of a diarylamine of the formula VIII



wherein R and R<sub>1</sub>-R<sub>5</sub> have meaning as defined above with a haloacetyl chloride, preferably chloroacetyl chloride, advantageously at elevated temperature, e.g. near 100°C, to obtain a compound of the formula IX



wherein R and R<sub>1</sub>-R<sub>5</sub> have meaning as defined hereinabove. Cyclization of a compound of formula IX is carried out under conditions of Friedel-Crafts alkylation in an inert solvent, such as dichlorobenzene, in the presence of Friedel-Crafts catalysts, e.g. aluminum chloride and ethylaluminum dichloride, at elevated temperature, e.g. at 120-175°C.

The diarylamines of formula VIII can be prepared by an Ullmann condensation as described hereinabove and other methods known in the art, e.g. a Buchwald coupling reaction.

For example, the diarylamines of formula VIII wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub> and R<sub>5</sub> are fluoro and R<sub>3</sub> is hydrogen can be prepared by reacting the corresponding aniline (4-ethyl- or 4-methyl-aniline)

with pentafluorobenzene in the presence of a strong base such as lithium amide or n-butyllithium, as generally described in J. of Fluorine Chemistry 5, 323 (1975).

Esters of the carboxylic acids of formula I are prepared by condensation of the carboxylic acid, in the form of a salt or in the presence of a base, with a halide (bromide or chloride) corresponding to the esterifying alcohol (such as benzyl chloroacetate) according to methodology well known in the art, e.g. in a polar solvent such as dimethyl formamide, and if required further modifying the resulting product.

For example, if the esterification product is itself an ester, such can be converted to the carboxylic acid, e.g. by hydrogenolysis of a resulting benzyl ester. Also if the esterification product is itself a halide, such can for instance be converted to the nitrooxy derivative by reaction with e.g. silver nitrate.

For example, the compounds of formula Ia are preferably prepared by condensing a salt of a carboxylic acid of formula I above with a compound of formula



wherein x is a leaving group and  $R_a$  is a carboxy protecting group to obtain a compound of formula I in carboxy protected form, and subsequently removing the protecting group  $R_a$ .

The esterification can be carried out under esterification conditions known in the art, e.g. in a polar solvent such as dimethylformamide, at a temperature in the range from room temperature to about 100°, preferably in the range from 40 to 60°.

The salt of the acid of formula Ia is preferably an alkali metal salt, e.g. the sodium salt, which may be prepared in situ.

Leaving group X is preferably halo, e.g. chloro or bromo, or lower alkylsulfonyloxy, e.g. methanesulfonyloxy.

The carboxy protecting group  $R_a$  is preferably benzyl.

The resulting benzyl esters can be converted to the free acids of formula Ia preferably by hydrogenolysis with hydrogen in the presence of e.g. a Pd/C catalyst in acetic acid at

atmospheric pressure or under Parr hydrogenation at a temperature ranging from room temperature to about 50°C.

The invention includes any novel starting materials and processes for their manufacture.

Finally, compounds of the invention are either obtained in the free form, or as a salt thereof if salt forming groups are present.

The acidic compounds of the invention may be converted into metal salts with pharmaceutically acceptable bases, e.g. an aqueous alkali metal hydroxide, advantageously in the presence of an ethereal or alcoholic solvent, such as a lower alkanol. Resulting salts may be converted into the free compounds by treatment with acids. These or other salts can also be used for purification of the compounds obtained. Ammonium salts are obtained by reaction with the appropriate amine, e.g. diethylamine, and the like.

Compounds of the invention having basic groups can be converted into acid addition salts, especially pharmaceutically acceptable salts. These are formed, for example, with inorganic acids, such as mineral acids, for example sulfuric acid, a phosphoric or hydrohalic acid, or with organic carboxylic acids, such as (C<sub>1</sub>-C<sub>4</sub>)alkanecarboxylic acids which, for example, are unsubstituted or substituted by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, succinic, maleic or fumaric acid, such as hydroxycarboxylic acids, for example glycolic, lactic, malic, tartaric or citric acid, such as amino acids, for example aspartic or glutamic acid, or with organic sulfonic acids, such as (C<sub>1</sub>-C<sub>4</sub>)-alkylsulfonic acids (for example methanesulfonic acid) or arylsulfonic acids which are unsubstituted or substituted (for example by halogen). Preferred are salts formed with hydrochloric acid, methanesulfonic acid and maleic acid.

In view of the close relationship between the free compounds and the compounds in the form of their salts, whenever a compound is referred to in this context, a corresponding salt is also intended, provided such is possible or appropriate under the circumstances.

The compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.

The pharmaceutical compositions according to the invention are those suitable for enteral, such as oral or rectal, transdermal, topical, and parenteral administration to mammals,

including man, to inhibit COX-2-activity, and for the treatment of COX-2 dependent disorders, and comprise an effective amount of a pharmacologically active compound of the invention, alone or in combination, with one or more pharmaceutically acceptable carriers.

More particularly, the pharmaceutical compositions comprise an effective cyclooxygenase-2 inhibiting amount of a compound of the invention which is substantially free of cyclooxygenase-1 inhibiting activity and of side effects attributed thereto.

The pharmacologically active compounds of the invention are useful in the manufacture of pharmaceutical compositions comprising an effective amount thereof in conjunction or admixture with excipients or carriers suitable for either enteral or parenteral application. Preferred are tablets and gelatin capsules comprising the active ingredient together with a) diluents, e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g. silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders e.g. magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone; if desired d) disintegrants, e.g. starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners. Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about 1 to 50%, of the active ingredient.

Tablets may be either film coated or enteric coated according to methods known in the art.

Suitable formulations for transdermal application include an effective amount of a compound of the invention with carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound

of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.

Suitable formulations for topical application, e.g. to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, for example, for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for dermal application, e.g. for the treatment of skin cancer, for example, for prophylactic use in sun creams, lotions sprays and the like. In this regard it is noted that compounds of the present invention, for example the compounds of examples 2 and 9 hereinafter, are capable of absorbing UV rays in the range of 290-320 nm while allowing passage of tanning rays at higher wavelengths. They are thus particularly suited for use in topical, including cosmetic formulations as aforesaid well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives. Formulations suitable for topical application can be prepared e.g. as described in U.S. patent 4,784,808. Formulations for ocular administration can be prepared e.g. as described in U.S. patent 4,829,088 and 4,960,799.

The pharmaceutical formulations contain an effective COX-2 inhibiting amount of a compound of the invention as defined above, either alone or in combination with another therapeutic agent.

Suitable additional active agents for use in relation to the treatment of neoplasia include e.g. any of the anti-neoplastic agents or radioprotective agents recited in the aforementioned International Patent Publication WO 98/16227 commencing at page 24, line 19.

In conjunction with another active ingredient, a compound of the invention may be administered either simultaneously, before or after the other active ingredient, either separately by the same or different route of administration or together in the same pharmaceutical formulation.

The dosage of active compound administered is dependent on the species of warm-blooded animal (mammal), the body weight, age and individual condition, and on the form of administration. A unit dosage for oral administration to a mammal of about 50 to 70 kg may contain between about 5 and 500 mg, of the active ingredient.

The present invention also relates to methods of using the compounds of the invention and their pharmaceutically acceptable salts, or pharmaceutical compositions thereof, in mammals for inhibiting COX-2 and for the treatment of COX-2 dependent conditions as described herein, e.g. inflammation, pain, rheumatoid arthritis, osteoarthritis, ocular disorders, in particular ocular inflammatory disorders, glaucoma and dry eye disease.

Further the invention relates to use of the compounds of the invention for the preparation of medicaments for treatment of COX-2 diseases and conditions.

Particularly the present invention relates to a method of selectively inhibiting cyclooxygenase-2 activity in a mammal without substantially inhibiting cyclooxygenase-1 activity which comprises administering to a mammal in need thereof an effective cyclooxygenase-2 inhibiting amount of a compound of the invention.

Thus the present invention also relates to a method of treating cyclooxygenase-2 dependent disorders in mammals, which comprises administering to a mammal in need thereof an effective cyclooxygenase-2 inhibiting amount of a compound of the invention.

More particularly the present invention relates to a method of treating cyclooxygenase-2 dependent disorders in mammals while substantially eliminating undesirable side effects associated with cyclooxygenase-1 inhibiting activity which comprises administering to a mammal in need thereof an effective cyclooxygenase-2 inhibiting amount of a compound of the invention which is substantially free of cyclooxygenase-1 inhibiting activity.

More specifically such relates to a method of treating rheumatoid arthritis, osteoarthritis, pain or inflammation in mammals without causing undesirable gastrointestinal ulceration, which method comprises administering to a mammal in need thereof a correspondingly effective amount of a compound of the invention.

The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees Centigrade. If not mentioned otherwise, all evaporations are performed under reduced pressure, preferably between about 15 and 100 mm Hg (= 20-133 mbar). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g. microanalysis and

spectroscopic characteristics (e.g. MS, IR, NMR). Abbreviations used are those conventional in the art.



## EXAMPLES

### Example 1

(a) N,N-dimethyl-5-methyl-2-(2',4'-dichloro-6'-methylanilino)phenylacetamide (1.5 g, 4.3 mmol) is hydrolyzed with 6N NaOH (70 ml) as a two phase solution with n-BuOH (40 ml) at reflux temperature for 14 hours. After cooling to room temperature, the mixture is poured over ice (100 ml). Toluene (100 ml) is added and the mixture transferred to a separatory funnel. The aqueous phase is brought to a pH of 1 with 3 N HCl. The organic phase is separated and the aqueous phase re-extracted with toluene (100 ml). The combined organic solution is dried ( $\text{MgSO}_4$ ) and concentrated under high vacuum (35 - 50 mbar), on a rotovap, taking care not to warm above 50°. Upon crystallization from  $\text{Et}_2\text{O}$ /hexane, 5-methyl-2-(2',4'-dichloro-6'-methylanilino)phenylacetic acid is obtained as a tan solid, m.p. 137-141°.

The starting material, N,N-dimethyl-5-methyl-2-(2',4'-dichloro-6'-methylanilino)phenylacetamide is prepared in the following manner:

5-Methyl-2-iodobenzoic acid (100 g, 0.38 mol) is dissolved in THF (350 ml) and cooled in an ice bath. Borane-THF complex (380 ml of 1M in THF, 0.38 mol) is added dropwise. After addition is complete, the reaction is warmed to room temperature and stirred for 14 hours. The mixture is transferred to a large erlenmeyer flask, cooled in an ice bath, and carefully quenched with water (250 ml). Evaporation of the THF on a rotovap gives a white suspension which is treated with additional water (1L) and then filtered and dried in a vacuum dessicator over  $\text{P}_2\text{O}_5$  to give 2-iodo-5-methylbenzyl alcohol as a white solid, m.p. 82-85°.

The benzylic alcohol (99.8 g, 0.38 mol) is dissolved in 48% HBr (500 ml) and heated to reflux temperature for 4 hours. The resulting benzylic bromide is isolated as a yellow solid by pouring the cooled mixture into a large volume (1.5 L) of water followed by filtration. The benzylic bromide (caution: lachrymator) is dissolved in EtOH (400 ml) and stirred at room temperature. Sodium cyanide (56 g, 1.14 mol) is dissolved in a minimum amount (~100 ml) of water and then added to the ethanolic solution of the benzylic bromide. The reaction is heated to reflux temperature for 3 hours and then cooled to room temperature. Ethanol is removed on a rotovap and the residue washed with a large volume (1 L) of water. The resulting 2'-iodo-5'-methylphenylacetone nitrile is isolated as a white solid, m.p. 77-79° by filtration.

The nitrile (94.5 g, 0.37 mol) is dissolved in EtOH (350 ml) and treated with NaOH (29.4 g, 0.74 mol) which has been dissolved in water (200 ml). The reaction is heated to reflux temperature for 14 hours. After cooling to room temperature, ethanol is removed on a rotovap and 6N HCl added until the pH = 1. The solid 5-methyl-2-iodophenylacetic acid is filtered off and washed with water (2 X 500 ml). After drying over P<sub>2</sub>O<sub>5</sub> in a vacuum dessicator, the solid 5-methyl-2-iodophenyl acetic acid (mp 112-114°, 83 g, 0.30 mol) is dissolved in CH<sub>2</sub>Cl<sub>2</sub> (450 ml) that contains several drops of DMF. To the solution thionyl chloride (32 ml, 0.450 mol) is added and the reaction heated to reflux temperature overnight. After cooling to room temperature, the reaction mixture is diluted with additional CH<sub>2</sub>Cl<sub>2</sub> (500 ml) and washed with water (2 X 250 ml), saturated NaHCO<sub>3</sub> (250 ml) and brine (250 ml). The solution is dried (MgSO<sub>4</sub>) and concentrated on a rotovap to give 5-methyl-2-iodophenylacetyl chloride as a yellowish oil.

Dimethylamine (200 ml of 2 M solution in THF) is added dropwise to a solution of 5-methyl-2-iodophenylacetyl chloride in Et<sub>2</sub>O (500 ml) which is cooled in an ice bath. After the addition is complete, EtOAc (350 ml) is added and the solution is washed with water (350 ml), brine (250 ml) and dried (MgSO<sub>4</sub>). Evaporation on a rotovap and trituration with 1:1 Et<sub>2</sub>O/hexanes gives N,N-dimethyl-5-methyl-2-iodophenylacetamide as a light tan solid, m.p. 47-49°.

N,N-Dimethyl-5-methyl-2-iodophenylacetamide (3.5 g, 11.5 mmol) and 2,4-dichloro-6-methylaniline (4.1 g, 23 mmol) are stirred in xylenes (100 ml) with copper powder (0.18 g, 2.9 mmol), copper(I) iodide (0.55 g, 2.9 mmol) and anhydrous potassium carbonate (1.6 g, 11.5 mmol). The reaction is heated to reflux temperature for 48 hours. While still slightly warm (40°) the brown suspension is filtered through a pad of Celite, which in turn is rinsed with toluene (75 ml). The filtrate is evaporated on a rotovap and flash chromatographed on silica gel (R<sub>f</sub> 0.30 in 40% EtOAc/hexane) to give N,N-dimethyl-5-methyl-2-(2',4'-dichloro-6'-methylanilino)phenylacetamide as an off-white crystalline solid, m.p. 119-124°.

The following compounds of Formula I wherein the R substituents are as indicated in Table 1 are similarly prepared.




Table 1

Example No	R	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>	m. p. °C
2	CH <sub>3</sub>	F	F	H	F	F	153-156
3	CH <sub>3</sub>	Cl	H	H	H	Cl	168-170
4 <sup>1</sup>	CH <sub>3</sub>	Cl	H	H	H	Cl	318-320
5 <sup>2</sup>	CH <sub>3</sub>	Cl	H	H	H	Cl	>300
6	CH <sub>3</sub>	Cl	H	H	H	F	158-159
7	CH <sub>3</sub>	Cl	H	CH <sub>3</sub>	H	Cl	179-182
8	CH <sub>3</sub>	Cl	H	H	H	CH <sub>3</sub>	138-140
9	CH <sub>3</sub>	F	H	F	H	Cl	157-159
10	CH <sub>3</sub>	F	H	Cl	H	Cl	178-180
11	CH <sub>3</sub>	Cl	H	F	H	CH <sub>3</sub>	154-156
12	CH <sub>3</sub> CH <sub>2</sub>	F	H	H	H	Cl	147-148
13	CH <sub>3</sub> CH <sub>2</sub>	Cl	H	H	H	CH <sub>3</sub>	125-126
14	CH <sub>3</sub> CH <sub>2</sub>	F	F	H	H	F	138-140

Example No	R	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>	m. p. °C
15	CH <sub>3</sub> CH <sub>2</sub>	F	F	C <sub>2</sub> H <sub>5</sub> O	F	F	131-132
16	CH <sub>3</sub> CH <sub>2</sub>	Cl	H	F	H	F	160-162
17	CH <sub>3</sub> CH <sub>2</sub>	Cl	H	Cl	H	F	169-171
18	CH <sub>3</sub> CH <sub>2</sub>	F	F	H	F	F	165-169 <sup>3</sup>
19	CH <sub>3</sub> CH <sub>2</sub>	Cl	H	Cl	H	CH <sub>3</sub>	180-183
20	CH <sub>3</sub> CH <sub>2</sub>	F	H	Cl	H	CH <sub>3</sub>	153-156
21	CH <sub>3</sub> CH <sub>2</sub>	F	H	F	H	CH <sub>3</sub>	143-145
22	CH <sub>3</sub> CH <sub>2</sub>	Cl	H	F	H	CH <sub>3</sub>	151-154
23	CH <sub>3</sub>	Cl	H	OH	H	F	180-182

<sup>1</sup> - potassium salt; <sup>2</sup> - sodium salt; <sup>3</sup> - after recrystallisation from cyclohexane.

The 5-ethyl-2-iodo-N,N-dimethylphenylacetamide starting material for Examples 12 to 17 is prepared as follows:

AlCl<sub>3</sub> (303g, 2.27 mol) is placed in a 3-necked flask fitted with a thermometer and a dropping funnel. While stirring DMF (50 ml) is added dropwise and the temperature rises to about 60°. The mixture is cooled down to 45°, and oxindole (33 g, 0.25 mol) is added in 3 portions. After an additional 10 minutes, acetyl chloride (36 ml, 0.5 mol) is added. The mixture is stirred for an additional 30 minutes at room temperature. The mixture is poured onto ice (3000 g). This results in the formation of a solid which is filtered off, washed first with water and then with cold methanol (1000 ml), and then dried to give 5-acetyloxindole.

The 5-acetyloxindole (54 g, 308 mmol), acetic acid (400 ml) and palladium on carbon (10%, 5 g) are combined and treated with hydrogen for 14 hours at 55 psi. The catalyst is removed by filtering through a bed of Celite, the filtrate is concentrated under reduced pressure and the residue is treated with ether to give 5-ethyloxindole

5-Ethyloxindole (~54 g, ~335 mmol), ethanol (750 ml), water (150 ml) and potassium hydroxide (65 g, 1.62 mol) are combined and heated at reflux for 3 days. The mixture is allowed to cool and then filtered through a bed of Celite. The filtrate is concentrated under reduced pressure, water is added and the pH adjusted to 6.5. The precipitate is filtered off, washed with water and dried in an oven overnight to yield 5-ethyl-2-aminophenylacetic acid.

A mixture of water (405 ml) and concentrated HCl (48 ml) is stirred and cooled to 0°. 5-Ethyl-2-aminophenylacetic acid (53.7 g, 300 mmol) is slowly added while maintaining the temperature at 0-2°C. After this addition a solution of sodium nitrite (22.2 g, 322 mmole) in 60 ml water is added dropwise over 30 minutes keeping the temperature at 0-2°. After a further 20 minutes a solution of potassium iodide (48 g, 290 mmol) in 18ml conc HCl and 130 ml water is added dropwise while keeping the temperature below 10°C. The reaction mixture is allowed to warm to room temperature and then heated to reflux for 2 hours. The mixture is extracted with ethyl acetate and ether (1:1 mixture, 4 x 300 ml), the organic layer is then washed first with a 30% aqueous solution of sodium thiosulfite and then with a sodium hydroxide solution (0.1M) before being acidified to pH 6 and extracted with ethyl acetate. This solution is washed with saturated brine, dried (magnesium sulfate), filtered, and the solvent removed under reduced pressure. The residue is treated with hexane to yield 5-ethyl-2-iodophenylacetic acid.

5-Ethyl-2-iodophenylacetic acid is dissolved in methylene chloride (400 ml) and DMF (1 ml) is added. Thionyl chloride (21 ml, 300 mmole) is then added dropwise over 20 minutes. The mixture is heated to reflux and heating continued for 3.5 hours when the mixture is cooled and ice-water (400 ml) and methylene chloride (300 ml) are added. The layers are separated, the organic layer is washed with a sodium bicarbonate solution, saturated brine, dried (magnesium sulfate), and evaporated under reduced pressure to yield 5-ethyl-2-iodophenylacetyl chloride.

The acid chloride (46 g, 150 mmol) is dissolved in ether (500 ml) and stirred at -35°. Dimethylamine (250 ml of 2M solution in THF, 500 mmol) is added dropwise at -35° and the mixture allowed to warm to room temperature and then stirred for 60 hours. Ethyl acetate and water are added and the layers separated. The organic layer is washed with saturated brine and the combined aqueous layers washed with ether. The combined organic layers are now dried (magnesium sulfate), and the solvent is removed under reduced pressure. Hexane is added to yield N,N-dimethyl 5-ethyl-2-iodophenylacetamide as a solid.

The N,N-dimethyl-5-ethyl-phenylacetamide starting materials for Examples 18 and 19 are prepared in the following manner:

N,N-Dimethyl-2-iodophenylacetamide (60 g, 0.208 mol), 2',3',5',6'-tetrafluoroaniline (100 g, 0.606 mol), copper powder (6.6 g, 0.104 mol), copper(I) iodide (19.8 g, 0.104 mol) and anhydrous potassium carbonate (28.7 g, 0.208 mol) are stirred together in 1000 ml of xylenes. The reaction is heated to reflux temperature for 48 hours. While still slightly warm (40°) the brown suspension is filtered through a pad of Celite which in turn is rinsed with toluene (250 ml). The filtrate is evaporated on a rotovap and then flash chromatographed on silica-gel (Rf 0.25 in 30% EtOAc/hexane). Crystallization from pentane/Et<sub>2</sub>O gives N,N-dimethyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetamide, m.p. 109-110°.

Under an inert atmosphere, acetyl chloride (29.1 ml, 0.385 mol) is slowly added to a suspension of aluminum chloride (51.2 g, 0.385 mol) stirred in 1,2-dichloroethane (750 ml). After stirring at room temperature for 1 hour a yellow solution is obtained. The solution is cooled in an ice bath and N,N-dimethyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetamide (40 g, 0.123 mol) is added. The reaction is allowed to warm to room temperature and then warmed to 80° for 0.5 hours. The reaction is poured over ice and extracted with EtOAc (2 x 750 ml). The organic extract is washed with water (750 ml), saturated NaHCO<sub>3</sub> solution (500 ml) and brine (500 ml). Evaporation on a rotovap and trituration with Et<sub>2</sub>O gives N,N-dimethyl-5-acetyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetamide as a white solid, m.p. 112-114°.

N,N-dimethyl-5-acetyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetamide (30 g, 0.802 mol) is dissolved in HOAc (150 ml) and hydrogenated (55 psi) with a 10% Pd/C (1.5 g) catalyst for 8 hours. The catalyst is removed by filtration through Celite and the filtrate poured into water (500 ml) and EtOAc (500 ml). The organic layer is washed with water (750 ml), neutralized with saturated Na<sub>2</sub>CO<sub>3</sub> solution (500 ml) and washed with brine (500 ml). Evaporation on a rotovap followed by trituration with hexanes gives N,N-dimethyl-5-ethyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetamide, m.p. 105-106°.

The N,N-Dimethyl 5-ethyl-2-(4'-chloro-2'-fluoro-6'-methylanilino)phenylacetamide starting materials for Examples 21 and 22 are prepared as follows:

Ullmann condensation of N,N-dimethyl-5-ethyl-2-iodo-phenylacetamide with 2-bromo-4-chloro-6-fluoroaniline according to the procedure described in Example 1 yields N,N-dimethyl-5-ethyl-2-(2'-bromo-4'-chloro-6'-fluoroanilino)phenylacetamide.

N,N-Dimethyl-5-ethyl-2-(2'-bromo-4'-chloro-6'-fluoroanilino)phenylacetamide (2.5 g, 6.0 mmole) is combined with DMF (10 ml), triethylamine (10 ml), tri-*o*-tolylphosphine (0.5 g, 1.6 mmole), tetramethyltin (4 ml, 5.16 g, 28.9 mmole) and palladium acetate (0.25 g, 1.1 mmole), and the mixture heated in a sealed tube for 3 days at 95°. The tube is allowed to cool and carefully opened. Water and ethyl acetate are added to the reaction and the mixture separated. The organic fraction is washed with a dilute NaCl solution (2 X 50 ml). The combined aqueous fractions are then washed with ethyl acetate and the combined organic fractions are then dried (magnesium sulfate). The material is absorbed onto a small amount of silica gel and purified by flash chromatography (on silica, ethyl acetate:hexanes, 1:4 to 1:1) to give N,N-dimethyl-5-ethyl-2-(4'-chloro-2'-fluoro-6'-methylanilino)phenylacetamide.

The 2-chloro-4-pivaloyloxy-6-fluoroaniline starting material for example 23 is prepared in the following manner:

To a mixture of 7.0 g (0.045 mol) of 3-fluoro-4-nitrophenol and 6.7 g (0.067 mol) of triethylamine in 20 ml of methylene chloride cooled to 0° is added 6.5 g (0.054 mol) of pivaloyl chloride in a dropwise manner. The reaction is allowed to warm to room temperature and stirred overnight. The reaction is quenched with water and extracted with ethyl acetate. The organic layer is washed successively with 1 N hydrochloric acid, saturated aqueous sodium bicarbonate, and saturated brine, and then dried over magnesium sulfate. Filtration and removal of the solvents gives 10.5 g of crude 2-fluoro-4-pivaloyloxy-nitrobenzene which is dissolved in 200 ml of absolute ethanol. To the solution is added 0.9 g of 5% palladium on carbon, and the mixture is then hydrogenated under 30 psi hydrogen for two hours. The catalyst is filtered and the solvent removed to give 2-fluoro-4-pivaloyloxyaniline.

A mixture of 7.3 g (0.035 mol) of 2-fluoro-4-pivaloyloxyaniline and 5.1 g (0.038 mol) of N-chlorosuccinimide in 50 ml of fluorobenzene is heated to reflux under a nitrogen atmosphere


for two hours. After cooling to room temperature, the solvent is removed, water is added, and the mixture is extracted with ethyl acetate. The organic layer is washed with 1 N sodium hydroxide, and saturated brine, and dried over magnesium sulfate. Filtration and removal of the solvents gives a residue which is purified by silica gel chromatography (20% ethyl acetate/hexane) to give 2-chloro-4-pivaloyloxy-6-fluoroaniline.

Conversion of 2-chloro-4-pivaloyloxy-6-fluoroaniline to 5-methyl-2-(2'-chloro-4'-hydroxy-6'-fluoroanilino)phenylacetic acid is carried out in a manner similar to that described in Example 1, the pivaloyl group being hydrolyzed in the last step along with the dimethylamide to give the final product.

#### Example 24

5-Ethyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetic acid (1.0 g, 3.06 mmol) in THF (100 ml) is treated with 1 N sodium hydroxide (3.06 ml, 3.06 mmol) for 1 hour. The mixture is concentrated on a rotovap and then dried by evaporating first with THF (2 X 100 ml) and then with benzene (2 X 100 ml). The remaining off-white sodium salt of 5-ethyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetic acid is dried under high vacuum overnight. Sodium 5-ethyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetate (0.5 g, 1.43 mmol) and benzyl 2-bromoacetate (272  $\mu$ l, 1.72 mmol) are stirred at 50° in dimethylformamide (50 ml) for 14 hours. The reaction mixture is cooled to room temperature and partitioned between EtOAc (200 ml) and water (200 ml). The organic layer is washed again with water (2 X 200 ml), brine (100 ml), dried (MgSO<sub>4</sub>) and concentrated on a rotovap. The crude benzyl ester is flash chromatographed on silica (10-15% EtOAc/hexane) to provide the benzyloxycarbonylmethyl ester of 5-ethyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetic acid as a colorless oil. The oil is dissolved in HOAc (20 ml) and hydrogenated (55 psi) with a 10% Pd/C (0.1 g) catalyst for 1 hour. The catalyst is removed by filtration through Celite and the filtrate poured into water (200 ml) and EtOAc (200 ml). The organic layer is washed with water (250 ml) and brine (100 ml). Evaporation on a rotovap and trituration with Et<sub>2</sub>O/hexanes gives the ester, carboxymethyl 5-ethyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetate, m.p. 151-153°, of the formula (1a), wherein R is ethyl, R<sub>1</sub> = R<sub>2</sub> = R<sub>4</sub> = R<sub>5</sub> = Fluoride and R<sub>3</sub> = H.





Similarly compounds of formula (1a), wherein the R substituents are as indicated in Table 2 are prepared:

Table 2

Example No	R	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>	m. p. °C
25	CH <sub>3</sub> CH <sub>2</sub>	Cl	H	Cl	H	CH <sub>3</sub>	123-125
26	CH <sub>3</sub> CH <sub>2</sub>	Cl	H	H	H	Cl	124-126
27	CH <sub>3</sub> CH <sub>2</sub>	F	H	F	H	Cl	142-144
28	CH <sub>3</sub> CH <sub>2</sub>	Cl	H	Cl	H	F	132-134
29	CH <sub>3</sub> CH <sub>2</sub>	Cl	H	H	H	F	106-108
30	CH <sub>3</sub>	F	H	Cl	H	Cl	148-150
31	CH <sub>3</sub>	Cl	H	H	H	Cl	125-126
32	CH <sub>3</sub>	Cl	H	H	H	F	96-98
33	CH <sub>3</sub>	F	H	F	H	Cl	

### Example 34

5-Ethyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetic acid (1.0 g, 3.06 mmol) in THF (100 ml) is treated with 1 N sodium hydroxide (3.06 ml, 3.06 mmol) for 1 hour. The mixture is concentrated on a rotovap and the residue is then treated and evaporated to dryness first with THF (2 x 100 ml) and then with benzene (2 x 100 ml). The remaining off-white sodium salt of 5-ethyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetic acid is dried under high vacuum overnight.

The sodium 5-ethyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetate (2.0 g, 6.2 mmol) is dissolved in DMF (70 ml) and treated with 1-bromo-4-chlorobutane (1.2 g, 6.9 mmol) at room temperature overnight. The reaction mixture is concentrated under high vacuum (35-50 mbar) on a rotovap. The resulting oil is partitioned between water (200 ml) and Et<sub>2</sub>O (200 ml). The organic layer is washed with brine (100 ml), dried (MgSO<sub>4</sub>) and concentrated on a rotovap to give the chlorobutyl ester as a light-brown oil. The chlorobutyl ester is dissolved in CH<sub>3</sub>CN (100 ml) and treated with silver nitrate (8.7 g, 50 mmol) at reflux temperature for 18 hours. The reaction is cooled to room temperature and the solvent removed on a rotovap. The residue is partitioned between CH<sub>2</sub>Cl<sub>2</sub> (200 ml) and water (200 ml). The organic layer is dried (MgSO<sub>4</sub>), concentrated and flash-chromatographed (5% EtOAc/hexane) to give nitrooxybutyl 5-ethyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetate as a clear oil.

### Example 35

Sodium 5-ethyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetate (7.3 g, 20.9 mmol) is dissolved in DMF (100 ml) and treated with benzyl 2-methyl-2-bromopropionate (6.2 g, 24.2 mmol) at 50° for 96 hours. The reaction mixture is cooled to room temperature, and concentrated under high vacuum (35-50 mbar) on a rotovap. The resulting oil is partitioned between water (200 ml) and Et<sub>2</sub>O (200 ml). The organic layer is washed with brine (100 ml), dried (MgSO<sub>4</sub>) and concentrated on a rotovap to give a light-brown oil. Flash chromatography (0-10% EtOAc/hexane) on silica-gel gives the ester as a light-red oil. The ester (1.5 g, 3.0 mmol) is dissolved in EtOAc (150 ml) and hydrogenated (55 psi) with a 10% Pd/C (0.3 g) catalyst for 1 hour. The catalyst is removed by filtration through Celite (500 ml). Evaporation on a rotovap followed by trituration with hexanes gives 1-carboxy-1-methylethyl 5-ethyl-2-(2',3',5',6'-tetrafluoroanilino)phenylacetate as a crystalline white solid, m.p. 104-108°.

Example 36

Isopropyl 5-methyl-2-(2'-fluoro-6'-trifluoromethylanilino)phenylacetate (2.9 g, 8.4 mmol) is dissolved in methanesulfonic acid (25 ml) and stirred at room temperature for 8 hours. The reaction mixture is slowly added to 200 ml of ice in a beaker. After the ice has melted, the solution is stirred to produce a white solid which is isolated by filtration. The solid is flash chromatographed on silica-gel using 35% EtOAc as an eluant to give 5-methyl-2-(2'-fluoro-6'-trifluoromethylanilino)phenylacetic acid as a white solid, m.p. 155-156°.

The starting material is prepared as follows:

2-Iodo-5-methylphenylacetic acid (20.0 g, 72 mmol) and a catalytic amount of 98% sulfuric acid (0.2 ml) are dissolved in isopropyl alcohol (200 ml) and heated to reflux temperature for 48 hours. The solvent is removed on a rotovap and the residual oil partitioned between EtOAc (500 ml) and saturated NaHCO<sub>3</sub> solution (500 ml). The organic layer is separated, dried (MgSO<sub>4</sub>) and concentrated on a rotovap. The residual oil is distilled using a kugelrohr apparatus to give a clear, colorless oil which solidifies on standing at room temperature to give isopropyl 2-iodo-5-methylphenylacetate, m.p. 48-50°.

Isopropyl 2-iodo-5-methylphenylacetate (10.0 g, 31 mmol), 2-amino-3-fluorobenzotrifluoride (20.0 g, 111 mmol), copper powder (1.1 g, 16 mmol), copper (I) iodide (3.1 g, 16 mmol) and K<sub>2</sub>CO<sub>3</sub> (4.3 g, 31 mmol) are stirred together in xylenes (200 ml). The reaction mixture is heated to reflux temperature for 48 hours. While still slightly warm (40°) the brown suspension is filtered through a pad of Celite, which in turn is rinsed with toluene (100 ml). The filtrate is evaporated on a rotovap and then flash chromatographed on silica-gel using 3-4% EtOAc in hexanes as the eluant. The product, isopropyl 5-methyl-2-(2'-fluoro-6'-trifluoromethylanilino)phenyl acetate, is isolated as a pale yellow oil.

Example 37

Similarly 5-methyl-2-(2',4'-dichloro-6'-trifluoromethylanilino)phenylacetic acid, m.p. 157-158° is prepared by a process as described in Example 36.

**Example 38**

N-(2,3,5,6-tetrafluorophenyl)-5-ethyloxindole (72.67 g; 0.235 mol, is slurried in water containing a little methanol (10% v/v; 253 ml), and sodium hydroxide solution (50 wt%; 16.1 ml) is added. The mixture is stirred at 80-85° for 2-4 hours, then cooled to ambient temperature. The reaction solution is partially concentrated under reduced pressure (25-30 mm). After removal of 50 ml of the solvent, the mixture is diluted with water (150 ml) and t-butyl methyl ether (250 ml). The cooled mixture is acidified to pH 6.5-7.0 with aqueous HCl (12.1 N; 19.5 ml), keeping the temperature at 0-5°. The aqueous layer is discarded and the organic layer is washed with water (250 ml). The organic layer is concentrated under reduced pressure (20-100 mm) while exchanging the solvent to toluene. After the more volatile components have been removed, the batch volume is adjusted to 400-450 ml. This mixture is warmed to 70°, clarified, concentrated to one-half volume, and cooled to 0°. After stirring at this temperature for 2 hours, the product is collected and is washed with toluene/heptane (10:90; 100 ml). The resulting solid is dried under reduced pressure at 50-60° for 4-8 hours to give 5-ethyl-2-(2', 3', 5', 6'-tetrafluoroanilino)phenylacetic acid of Example 18.

The starting material is prepared as follows:

4-Ethylaniline (242.36 g; 2.00 mol) is dissolved in dry tetrahydrofuran (900 ml). A solution of n-BuLi (2.5 M in hexanes, 800 ml; 2.00 mol) is added under N<sub>2</sub> with cooling maintaining the reaction temperature below 15°. After stirring for 1 hour at 10°, neat pentafluorobenzene (168.06 g; 1.00 mol) is added with cooling to the mixture, keeping the temperature at 10-20°. The reaction is stirred at ambient temperature for 1.5 hours, then aqueous HCl (6 N; 500 ml) is added slowly with vigorous stirring and cooling, keeping the reaction temperature below 35°. The quenched reaction is stirred at ambient temperature for 0.5-18 hours. The lower aqueous layer is separated, and the top organic phase is concentrated under reduced pressure (30-150 mm) to one-fourth volume. The concentrate is diluted with heptane (300 ml) and extracted with water (300 ml). The separated top organic layer is stirred over 230-400 mesh silica gel (50 g) and filtered. The filter cake is washed with heptane (4 X 50 ml). The combined filtrate and washings are concentrated under reduced pressure (20-30 mm) to give solid crude product. This material is recrystallized from hot heptane (200 ml) and collected at 0°. This


solid is washed with cold heptane (100 ml) and dried under reduced pressure at 40° to give pure N-(2',3',5',6'-tetrafluorophenyl)-4-ethylaniline.

The diphenylamine derivative (230.0 g; 0.854 mol; 1.0 eq) is treated with chloroacetyl chloride (192.96 g; 1.709 mol; 2.0 eq) at 100-115° for 2 hours (vigorous HCl evolution is controlled by rate of heating). The mixture is cooled to ambient temperature, then concentrated under reduced pressure (10-12 mm) to 80-90% of the original volume. 1,2-Dichlorobenzene (80 ml) is added and the diluted mixture is concentrated under reduced pressure (10-12 mm) until no more chloroacetyl chloride is found by GC analysis (30-40 ml distilled) to give crude N-(2',3',5',6'-tetrafluorophenyl)-N-chloroacetyl-4-ethylaniline in solution.

Anhydrous  $\text{AlCl}_3$  (170.84 g; 1.281 mol; 1.5 eq) was slurried with 1,2-dichlorobenzene (480 ml) under  $\text{N}_2$  and cooled to 0°. The crude product solution from the previous step (theoretically containing 295.34 g; 0.854 mol; 1.0 eq) is added slowly with vigorous stirring, keeping the temperature below 60°. A solution of  $\text{EtAlCl}_2$  (1.8 M in toluene; 733 ml; 1.319 mol; 1.7 eq) is added, and the vigorously stirred reaction mixture is heated to ~160°, distilling toluene (135-160°) at ambient pressure. Upon cessation of the distillation (~690 ml), the reaction temperature is held at 155-165° for 3.5-5 hours. The mixture is cooled to ambient temperature, then poured onto crushed ice (2.5 kg) with vigorous stirring under  $\text{N}_2$ . The reaction vessel is rinsed with 1,2-dichlorobenzene (50 ml). The cold quenched product slurry is filtered and the filtercake is washed sequentially with 10% 1,2-dichlorobenzene/heptane (100 ml) and heptane (100 ml). The material is dried under reduced pressure at 80-90° for 12-16 hours to give N-(2',3',5',6'-tetrafluorophenyl)-5-ethyloxindole.

**CLAIMS**

1. A compound of formula I



wherein R is methyl or ethyl;

R<sub>1</sub> is chloro or fluoro;

R<sub>2</sub> is hydrogen or fluoro;

R<sub>3</sub> is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy;


R<sub>4</sub> is hydrogen or fluoro; and

R<sub>5</sub> is chloro, fluoro, trifluoromethyl or methyl;

or a pharmaceutically acceptable salt thereof;

or a pharmaceutically acceptable prodrug ester thereof.



- 2 A compound of formula (1a)



wherein R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are as defined in claim 1; and pharmaceutically acceptable salts thereof.


3. A compound according to claim 1 or 2 wherein R is methyl or ethyl; R<sub>1</sub> is chloro or fluoro; R<sub>2</sub> is hydrogen; R<sub>3</sub> is hydrogen, fluoro, chloro, methyl or hydroxy; R<sub>4</sub> is hydrogen;

- and R<sub>5</sub> is chloro, fluoro or methyl; or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable prodrug ester thereof.
4. A compound according to claim 1 as disclosed in any of Examples 1 to 37; or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable prodrug ester thereof
  5. A pharmaceutical composition comprising an effective cyclooxygenase-2 inhibiting amount of a compound of claim 1 or 2 in combination with one or more pharmaceutically acceptable carriers.
  6. A method of treating cyclooxygenase-2 dependent disorders in mammals which comprises administering to a mammal in need thereof an effective cyclooxygenase-2 inhibiting amount of a compound according to claim 1 or 2.
  7. A method of selectively inhibiting cyclooxygenase-2 activity in a mammal without substantially inhibiting cyclooxygenase-1 activity which comprises administering to a mammal in need thereof an effective cyclooxygenase-2 inhibiting amount of a compound of claim 1 or 2.
  8. A method of treating rheumatoid arthritis, osteoarthritis, pain, inflammation, ocular inflammatory disorders, glaucoma or dry eye disease in mammals which comprises administering to a mammal in need thereof a correspondingly effective amount of a compound of claim 1 or 2.
  9. A method for the preparation of a compound of formula I which comprise:
    - (a) coupling a compound of formula II or IIa





wherein R has meaning as defined in claim 1;  $R_a$  is lower alkyl; and  $R_6$  and  $R_7$  represent lower alkyl; or  $R_6$  and  $R_7$  together with the nitrogen atom represent piperidino, pyrrolidino or morpholino;

with a compound of formula III




wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$  and  $R_5$  have meaning as defined in claim 1 in the presence of copper and cuprous iodide to obtain a compound of formula IV






and hydrolyzing the resulting compound of formula IV or IVa to a compound of formula I; or

(b) for compounds in which R represents ethyl, condensing a compound of formula V




wherein  $\text{R}_1\text{-R}_7$  have meaning as defined herein, with a reactive functional derivative of acetic acid, such as acetyl chloride, in a Friedel-Crafts acylation to reaction to obtain a compound of the formula VI



wherein  $R_1$ - $R_7$  have meaning as defined herein which is in turn hydrogenolyzed and then hydrolyzed to obtain a compound of formula I wherein R represents ethyl; or

(c) hydrolyzing a lactam of formula VII



wherein R and  $R_1$ - $R_5$  have meaning as defined herein, with a strong base; and

in above processes, if desired, temporarily protecting any interfering reactive groups and then isolating the resulting compound of the invention; and, if desired, converting any resulting compound into another compound of the invention; and/or if desired converting a free carboxylic acid of the invention into a pharmaceutically acceptable ester derivative thereof; and/or if desired, converting a resulting free acid into a salt or a resulting salt into the free acid or into another salt.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/05414

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C229/42 A61K32/195

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
----------	--	-----------------------

A	<p>WO 97 09977 A (YAKULT HONSHA KK ;YAMAZAKI RYUTA (JP); MATSUZAKI TAKESHI (JP); HAS) 20 March 1997 &amp; EP 0 865 788.A see claims; examples</p> <p>-----</p>	
---	--	--

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

2 February 1999

Date of mailing of the international search report

15/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Pauwels, G

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/05414

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9709977 A	20-03-1997	JP 9077664 A	25-03-1997
		CA 2230970 A	20-03-1997
		EP 0865788 A	23-09-1998
-----			